TGFB1 and chronic kidney disease: While direct mechanistic studies of Bailing capsules on these pathways are limited, the observed clinical benefits in serum creatinine reduction and CKD progression delay are consistent with the hypothesized modulation of TGF-β/Smad, RAS, and Wnt/β-catenin signaling.